Genmab A/S Stock Chart

Genmab A/S (LSIN) · Health Technology. stock live price and technical analysis view. Follow LSE data on Alerta Chart.

Checking data access...

About Genmab A/S

LSIN
Market Cap
$129.26B
P/E Ratio
14.91
Shares Out.
61.55M
Sector
Health Technology
Industry
Pharmaceuticals: Major

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

www.genmab.com

Related Markets

Market Hub:Stocks Hub

Need more analysis tools?

With Alerta Chart Pro Terminal, you can follow 4 charts at the same time, see depth (order book) data and set 25 active alerts.

Start for Free